DELAFIELD, Wis. (Stockpickr) – As part of a daily routine as an active trader or investor, one should always be tracking the stocks in the market that are making the biggest percentage gains and the biggest percentage losses.

Stocks that are making large moves to the upside are favorites among short-term traders because they can jump into these names and try to capture some of that massive volatility. Stocks that are making big-percentage moves either up or down are usually in play because their sector is becoming attractive or they have a major fundamental catalyst such as a recent earnings release. Sometimes stocks making big moves have been hit with an analyst upgrade or an analyst downgrade.

Regardless of the reason behind it, when a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits. If you time your trade correctly, combining with fundamental trends, discipline and sound money management, you will be well on your way to investment success.

With that in mind, let's take a closer look at a several stocks under $10 that are making large moves to the upside.

Arca Biopharma

Arca Biopharma (ABIO) - Get Report, a biopharmaceutical company, focuses on developing genetically targeted therapies for cardiovascular diseases. This stock is trading up 1.33% to 78 cents per share in Thursday's trading session.

Thursday's Range: $0.77-$0.80
52-Week Range: $0.65-$2.38
Thursday's Volume: 194,000
Three-Month Average Volume: 408,503

From a technical perspective, ABIO is trending modestly higher here back above its 50-day moving average of 78 cents per share with lighter-than-average volume. This stock recently formed a major bottoming chart pattern, after shares found buying interest at 66, 65, 65 and 69 cents per share over the last month. Following that bottom, shares of ABIO have started to spike higher and its now flirting with hits 50-day moving average. That move is quickly pushing shares of ABIO within range of triggering a major breakout trade above some key near-term overhead resistance levels. That trade will hit if ABIO manages to take out Thursday's intraday high of 80 cents per share and then above some more key near-term overhead resistance at 84 cents per share with high volume.

Traders should now look for long-biased trades in ABIO as long as it's trending above some key near-term support at 69 cents per share and then once it sustains a move or close above those breakout levels with volume that hits near or above 408,503 shares. If that breakout gets started soon, then ABIO will set up to re-test or possibly take out its next major overhead resistance levels at $1.06 to its 200-day moving average of $1.13, or even $1.25.

Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics (BCLI) - Get Report, a biotechnology company, develops adult stem cell therapies for neurodegenerative disorders, such as amyotrophic lateral sclerosis, Parkinson disease and multiple sclerosis. This stock is trading up 4.9% to $4.38 in Thursday's trading session.

Thursday's Range: $4.20-$4.43
52-Week Range: $2.81-$8.47
Thursday's Volume: 89,000
Three-Month Average Volume: 939,765

From a technical perspective, BCLI is spiking sharply higher here right off both its 50-day moving average of $4.13 and its 200-day moving average of $4.16 with lighter-than-average volume. This stock recently formed a triple bottom chart pattern, after shares found buying interest at $3.75, $3.72 and $3.77 a share. Following that bottom, shares of BCLI have started to spike higher and it broke out above some near-term overhead resistance levels at $4.04 to $4.25. That move is now quickly pushing shares of BCLI within range of triggering a much bigger breakout trade. That trade will hit if BCLI manages to clear some key near-term overhead resistance at $4.65 with high volume.

Traders should now look for long-biased trades in BCLI as long as it's trending above those triple bottom support levels and then once it sustains a move or close above $4.65 with volume that hits near or above 939,765 shares. If that breakout triggers soon, then BCLI will set up to re-test or possibly take out its next major overhead resistance levels at $5.50 to $6.50.

Sunesis Pharmaceuticals

Sunesis Pharmaceuticals (SNSS) - Get Report, a biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. This stock is trading up 5.1% to $2.27 in Thursday's trading session.

Thursday's Range: $2.18-$2.32
52-Week Range: $1.00-$8.46
Thursday's Volume: 495,000
Three-Month Average Volume: 1.31 million

From a technical perspective, SNSS is spiked sharply higher here right above some near-term support levels at $2 to $1.90 with decent upside volume flows. This move to the upside on Thursday is starting to push shares of SNSS within range of triggering a near-term breakout trade above some key overhead resistance levels. That trade will hit if SNSS manages to clear its 50-day moving average of $2.41 and then once it takes out some more key overhead resistance levels at $2.50 to $2.53 with high volume.

Traders should now look for long-biased trades in SNSS as long as it's trending above those key near-term support levels at $2 to $1.90 and then once it sustains a move or close above those breakout levels with volume that hits near or above 1.31 million shares. If that breakout triggers soon, then SNSS will set up to re-test or possibly take out its next major overhead resistance level at $2.94. Any high-volume move above that level will then give SNSS a chance to re-fill some of its previous gap-down-day zone form last October that started near $7.

This article is commentary by an independent contributor. At the time of publication, the author held TK positions in the stocks mentioned.